BioWorld - Monday, December 8, 2025

BioWorld Science

May 6, 2022

View Archived Issues

BCY-6033: EphA2-targeting BTC with efficacy in NSCLC PDX models

Read More

Enliven Therapeutics describes new Bcr-Abl kinase inhibitors

Read More

Silverback Therapeutics synthesizes TGFR-1 inhibitors and antibody-drug conjugates

Read More

CD38 inhibitors discovered at Napa Therapeutics, Buck Institute

Read More

Kymera Therapeutics presents STAT-degrading PROTACs

Read More

Vertex Pharmaceuticals patents CFTR modulators

Read More

Platform delivers siRNA targeting VEGF intravitreally for diabetic retinopathy

Read More

Turning Point and LaNova enter license agreement for LM-302 and collaboration on ADC programs

Read More

Insilico Medicine nominates preclinical candidate targeting MAT2A for MTAP-deleted cancers

Read More

Betta Pharmaceuticals presents preclinical results for cancer candidates BPI-371153 and BPI-442096

Read More

SPH-5030 demonstrates potent and selective activity in HER2-mutant cancer models

Read More

Orion enters agreement with Jemincare for Nav1.8 blocker for treatment of pain

Read More

Mosaic signs license agreement covering use of cowpea mosaic virus to treat cancer

Read More

Preclinical pipeline progress at Intellia Therapeutics

Read More

Clover reports neutralization findings from preclinical study of bivalent COVID-19 vaccine candidate

Read More

Taking aim at tumor metabolism, while taming toxicity

Read More